Pulmonary Embolism: An Update Based on the Revised AWMF-S2k Guideline.
| Autor: | Opitz CF; DRK Kliniken Berlin Westend, Spandauer Damm 130, Berlin, Germany., Meyer FJ; Lungenzentrum München (Bogenhausen-Harlaching), München Klinik gGmbH, Sanatoriumsplatz 2, München, Germany. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Hamostaseologie [Hamostaseologie] 2024 Apr; Vol. 44 (2), pp. 111-118. Date of Electronic Publication: 2024 Apr 30. |
| DOI: | 10.1055/s-0044-1779011 |
| Abstrakt: | Pulmonary embolism (PE) is the third most common acute cardiovascular disease. The risk of PE increases with age and mortality is high. Patients are stratified into hemodynamically stable versus unstable patients, as this has important implications for diagnosis and therapy. Since clinical signs and symptoms of acute PE are nonspecific, the clinical likelihood of PE is estimated to guide diagnostic pathways. D-dimer testing is performed in hemodynamically stable patients with low or intermediate probability of PE and the visualization of thromboembolism and its sequelae is commonly achieved with computed tomography pulmonary angiography (CTPA), supplemented by ultrasound techniques. With confirmed PE, another risk stratification estimates disease severity and defines intensity and setting of the ensuing treatment. The therapeutic spectrum ranges from outpatient treatment with initial oral anticoagulation to thrombolytic or interventional treatment in the intensive care unit or catheterization laboratory. In single cases, even acute surgical thrombectomy is attempted. Competing Interests: FJM has received honoraria for lectures from Jansen-Cilag, Boehringer and Novartis. CO has no conflict of interest. (Thieme. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|